Filing summary
Entity and period: The supplied filing is Rexahn Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, filed March 21, 2014. This does not match the request metadata identifying Opus Genetics, Inc. or “2013 Q4”; the filing reports annual results, not standalone fourth-quarter results.
Business context
Rexahn was a development-stage biopharmaceutical company focused primarily on cancer therapeutics. Its active oncology pipeline included Archexin (Phase IIa), RX-3117 (Phase I), and Supinoxin (Phase I); three additional candidates were preclinical. Serdaxin and Zoraxel were not being actively developed, and the company was seeking partners for them. Rexahn had no approved products or product sales.
Financial results and liquidity
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $7.979 million | $6.580 million |
| Net loss | $9.499 million | $6.227 million |
| Net loss per share, basic and diluted | $0.07 | $0.06 |
| Cash used in operating activities | $7.985 million | $6.620 million |
At year-end 2013, cash and cash equivalents were $18.688 million, restricted cash was $0.196 million, and marketable securities were $0.100 million. Total assets were $19.556 million, total liabilities $6.931 million, and stockholders’ equity $12.625 million. The company reported no debt instruments on its balance sheet. Warrant liabilities were $5.034 million, up from $2.842 million.
Operating cash use increased year over year. Financing activities provided $12.341 million in 2013, including $10.041 million of net proceeds from registered offerings and $2.210 million from warrant exercises. No operating margin is meaningful given the absence of revenue.
Changes and notable items
- Net loss increased about 53% year over year. General and administrative expense rose 57% to $4.260 million, principally due to investor-relations and financial-advisory costs, CEO-related compensation and recruiting, and other corporate expenses.
- Research and development expense declined 4.1% to $3.253 million. Rexahn said RX-3117 costs funded from a deferred Teva arrangement were not expensed in 2013; higher Supinoxin and Archexin trial-preparation costs partly offset the decrease.
- A noncash $1.366 million loss from the change in fair value of warrants contributed to the larger 2013 net loss; 2012 included a $0.664 million noncash gain.
- Teva declined to exercise its RX-3117 licensing option in August 2013. Rexahn retained worldwide development and commercialization rights, along with responsibility for future funding.
- Rexahn completed two 2013 registered direct offerings with combined gross proceeds of approximately $11.0 million, issuing common shares and warrants.
Outlook, risks and contingencies
Management stated that year-end cash, restricted cash and marketable securities, together with the January 2014 financing, were expected to fund minimum planned operating needs for at least 24 months. The company subsequently closed a January 2014 registered direct offering for $20.0 million gross. Management nevertheless said additional capital would be needed to continue development; financing may be unavailable or dilutive, and insufficient funds could force reductions in research and development.
Planned spending over the next 12 months included approximately $1.4 million for Archexin Phase II work, $4.1 million for RX-3117 and Supinoxin, $3.1 million for the preclinical pipeline and general R&D, $3.6 million for corporate expenses, and $0.140 million for facilities rent. These were estimates, not guaranteed spending or clinical milestones.
Key risks include uncertain clinical efficacy and safety, regulatory approval and trial timing, reliance on external research organizations and manufacturers, limited operating history and no product revenue, competition, intellectual-property challenges, and dependence on additional financing and future partners. Rexahn cited a Tokyo District Court action concerning a Japanese patent application for Supinoxin; success in correcting the patent claims was not assured. It also disclosed contractual research commitments and milestone-based license payments, including a $1.0 million KRICT payment upon specified marketing approval; that milestone had not occurred by year-end. The filing reported no proceedings under its Legal Proceedings item.
Archexin’s completed pancreatic cancer Phase IIa study reported median survival of 9.1 months among evaluable patients, compared with historical single-agent gemcitabine survival data of 5.65 months. The filing describes this as a comparison with historical data, not a randomized controlled comparison. Archexin’s metastatic renal cell carcinoma Phase IIa trial and RX-3117’s Phase Ib trial began in January 2014; Supinoxin’s Phase I trial began in August 2013.
Important facts for investors to verify
- Confirm the issuer and period: the source is Rexahn Pharmaceuticals’ FY2013 10-K, not an Opus Genetics filing or a quarterly report.
- Review the audited financial statements and subsequent-events note, including the $20.0 million January 2014 offering and post-year-end warrant exercises.
- Assess the cash runway against actual trial costs, operating cash burn, contractual obligations, and the possibility of further financing or dilution.
- Review full clinical-trial data and study designs, especially the limitations of comparing Archexin results with historical survival data.
- Check the status of the Supinoxin Japanese patent litigation and the company’s warrant terms and fair-value liability assumptions.